Mateusz Opyrchal, MD, PhD

Mateusz Opyrchal, MD, PhD, discusses the current state of biomarkers in triple-negative breast cancer.

Second-generation immuno-oncology studies hold great promise for breaking through the known barriers highlighted by earlier research against metastatic breast cancer.

Providing medical care to patients in the hospital setting has become increasingly complicated. Large amounts of clinical data need to be processed, and new rules governing resident and fellow hours have resulted in fragmented care.